Director at $BR sells 253 shares in insider sale

A recent insider sale at $BR caught the attention of market watchers as Robert N Duelks, a director at the company, sold 253 shares on 02-06-2026 for approximately $48,727. This transaction, representing about 1.2% of their holdings, was disclosed in a recent SEC filing. Following this sale, Duelks now retains ownership of 20,815 shares of this class of $BR stock.

Looking at $BR’s insider trading activity over the past 6 months, there have been a total of 11 transactions, with all 11 involving sales and no purchases by insiders. CEO Timothy C Gokey led the way with 5 sales totaling 146,171 shares and an estimated value of $38,048,902, followed by President Christopher John Perry and Corporate VP Thomas P Carey with 2 sales (11,020 shares) and 3 sales (10,214 shares), respectively. Duelks’ recent sale of 253 shares adds to the overall insider trading activity at $BR.

Shifting our focus to $BR’s hedge fund activity, there have been significant movements by institutional investors in the most recent quarter. A total of 464 institutional investors added shares of $BR stock to their portfolio, while 525 decreased their positions. Notable changes include AllianceBernstein L.P. adding 3,224,891 shares (+692.3%), T. Rowe Price Investment Management, Inc. removing 1,310,397 shares (-57.9%), UBS AM adding 869,092 shares (+65.9%), Van Eck Associates Corp adding 679,489 shares (+3228.4%), and other notable institutions adjusting their positions in $BR stock.

In terms of revenue, $BR reported revenues of $1.7 billion in Q2 2026, reflecting the company’s financial performance during that period.

Members of Congress have also been involved in trading $BR stock, with one purchase recorded in the past 6 months. Representative Dan Newhouse made a purchase of up to $15,000 on 12/31.

Lastly, analysts have provided price targets for $BR stock, with the median target standing at $250.0. Recent targets from various analysts include Kyle Peterson from Needham ($255.0), Puneet Jain from JP Morgan ($229.0), Peter Heckmann from DA Davidson ($228.0), Alex Kramm from UBS ($250.0), and James Faucette from Morgan Stanley ($256.0).

It is important to note that this article is not offering financial advice, and readers are encouraged to conduct their own research and due diligence. For more information on insider transactions, hedge fund activities, revenue updates, congressional trading, and price targets related to $BR, individuals can explore Quiver Quantitative’s various dashboards tracking these metrics.